Home LiteratureArticle Details
PMID: 18523885 Published · ppublish English

No association of TGFB1 L10P genotypes and breast cancer risk in BRCA1 and BRCA2 mutation carriers: a multi-center cohort study.

Breast cancer research and treatment ·Vol. 115 ·No. 1 ·2009-09-30

Rebbeck Timothy R, Antoniou Antonis C, Llopis Trinidad Caldes, Nevanlinna Heli, Aittomäki Kristiina, Simard Jacques, Spurdle Amanda B, , Couch Fergus J, Pereira Lutecia H Mateus, Greene Mark H, Andrulis Irene L, , Pasche Boris, Kaklamani Virginia, , Hamann Ute, Szabo Csilla, Peock Susan, Cook Margaret, Harrington Patricia A, Donaldson Alan, Male Allison M, Gardiner Carol Anne, Gregory Helen, Side Lucy E, Robinson Anne C, Emmerson Louise, Ellis Ian, , Peyrat Jean-Philippe, Fournier Joëlle, Vennin Philippe, Adenis Claude, Muller Danièle, Fricker Jean-Pierre, Longy Michel, Sinilnikova Olga M, Stoppa-Lyonnet Dominique, , Schmutzler Rita K, Versmold Beatrix, Engel Christoph, Meindl Alfons, Kast Karin, Schaefer Dieter, Froster Ursula G, Chenevix-Trench Georgia, Easton Douglas F

Abstract

The transforming growth factor beta-1 gene (TGFB1) is a plausible candidate for breast cancer susceptibility. The L10P variant of TGFB1 is associated with higher circulating levels and secretion of TGF-beta, and recent large-scale studies suggest strongly that this variant is associated with breast cancer risk in the general population.,To evaluate whether TGFB1 L10P also modifies the risk of breast cancer in BRCA1 or BRCA2 mutation carriers, we undertook a multi-center study of 3,442 BRCA1 and 2,095 BRCA2 mutation carriers.,We found no evidence of association between TGFB1 L10P and breast cancer risk in either BRCA1 or BRCA2 mutation carriers. The per-allele HR for the L10P variant was 1.01 (95%CI: 0.92-1.11) in BRCA1 carriers and 0.92 (95%CI: 0.81-1.04) in BRCA2 mutation carriers.,These results do not support the hypothesis that TGFB1 L10P genotypes modify the risk of breast cancer in BRCA1 or BRCA2 mutation carriers.

Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
Published
2009-09-30
Indexed
2009-04-23
Updated
2016-12-03
Language
English
Country/Region
Netherlands
NLM ID
8111104
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com